ArticleEJNMMI radiopharmacy and chemistry2025
Assessing the radiation-induced bystander effect in radionuclide therapy using targeted radiopharmaceuticals.
Article in EJNMMI radiopharmacy and chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Radiation Biology of Radiopharmaceuticals: Beyond External Beam Radiation Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- A Scoping Review of the Challenges and Future Perspectives in the Use of Alpha-Emitters for Metastatic Ovarian Cancer.Molecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundRadiation-induced biologic bystander effects (RIBBEs) where non-irradiated cells display radiation like responses are well established in the context of external beam radiotherapy. However, their presence and characteristics in radionuclide therapy have been explored in only a limited number of studies. With the growing application of radionuclide therapy, this study was designed to investigate RIBBEs using a targeting agent labeled with three different types of emitters, aiming to quantify the varying biological effects attributable to each radionuclide and to devise strategies for achieving maximum therapeutic effect.Trastuzumab antibody targeting human epidermal growth factor receptor 2 (HER2) was labeled with radionuclides of varying energy profile; Y-90 (β
resultsThe study highlights distinct cellular responses depending on the radionuclide employed, with significant bystander induced reductions in clonogenic survival observed for all radiolabeled formulations. Notably, HER2-overexpressing SK-OV-3 and SK-BR-3 cells displayed dose-dependent variations in survival, with
conclusionsThis study elucidates the complex interplay of direct and bystander effects in targeted radionuclide therapy, demonstrating that the therapeutic efficacy and cellular response depend on the specific radionuclide and its energy profile. The findings emphasize the need for further exploration of RIBBEs to optimize radionuclide-based cancer therapies to enhance their clinical efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.